2005 1st Half-Year Group Sales Up 21%

* France, including French overseas dependencies
** Germany, Italy, Spain, Portugal and Belgium
*** Distributors: other Group markets

Group sales increased by 22% during the second quarter of 2005, including for the first time sales of the IPI business, which was acquired in March 2005.  The Group reported organic sales growth of 18% and 20% for the second quarter and first half of 2005 respectively.

• In France, sales growth remained dynamic for the second quarter, up 21%, sustained by the recruitment of a high number of new patients.

• Subsidiaries organic sales growth, up 23% excluding IPI, surpassed for the first time in many years that realised by the Group's French operations, thanks in particular to strong sales growth in Germany.

• Distributors sales continued to grow, increasing 4% for the first half year.

The effect of the seasonality of treatments should slowdown sales growth slightly during the second half of 2005.  Nevertheless, the Group forecasts double digit organic sales growth and confirms the improvement in profitability after taking into account the increased resources dedicated to the development of allergen tablets.

[(3) Sales are presented in accordance with international accounting standards (IFRS), net of payment discounts, which amounted to € 0.13 million for the first half of 2004.